ReviewNAR cancer2025
Polymerase θ-what does it see, and why does it matter for cancer therapy?
Review in NAR cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Polymerase theta (Pol θ) is a DNA repair factor that has drawn much recent interest as a target for cancer therapy, since its inhibition is well-tolerated in most cells but is lethal in cancers deficient in breast cancer-associated (BRCA) genes ("synthetic lethality"). Its normal biological functions, as well as how these functions change in BRCA-deficient cancers, are only recently becoming clear, however. We review here recent progress in our understanding of the cellular regulatory mechanisms at work in determining if Pol θ sees DNA damage. At the molecular scale Pol θ then must notably see and repair diverse classes of damage, including (at least) conventional double strand breaks (made by e.g. ionizing radiation), as well as several types of damage associated with replication stress. We speculate on the mechanisms that could explain this flexibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.